Personalised Cancer Vaccine TG4050 in Resected Locally Advanced Head & Neck Squamous Cell Carcinoma (HNSCC) Patients
Time: 9:30 am
day: Day Two
Details:
- Reviewing TG4050, an individualised immunotherapy being developed for solid tumours that is based on Transgene’s myvac® technology and powered by NEC’s longstanding artificial intelligence (AI) and machine learning expertise
- Discussing how TG4050 is being evaluated in a randomised multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers
- Assesing 24-month follow up clinical and translational data from patients enrolled in the Phase I trial will be presented
